Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 6/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22116377 | 0.78 | ATR (0.48) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL22116376 | 0.78 | ATR (0.48) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL22116346 | 0.77 | KIF18A (0.50) | KIF18A | |
| SCHEMBL22116295 | 0.75 | HPGD (0.36) | — | |
| SCHEMBL22116332 | 0.74 | HSD11B1 (0.44) | ACACBKIF18A | |
| SCHEMBL22116413 | 0.74 | HPGD (0.39) | ACACBKIF18A | |
| SCHEMBL22116414 | 0.73 | ABL1 (0.43) | ACACBKIF18A | |
| SCHEMBL22116366 | 0.73 | ABL1 (0.43) | ACACBKIF18A | |
| SCHEMBL22116307 | 0.73 | KIF18A (0.42) | ACACBKIF18A | |
| SCHEMBL30611688 | 0.73 | ABL1 (0.43) | ACACBKIF18A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |